MARKHAM, Ontario, June 15, 2023 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. ("Sienna" or the "Company") (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a "Common Share") for the month of June 2023, representing $0.936 per Common Share on an annualized basis.
The dividend will be payable on July 14, 2023 to shareholders of record as at June 30, 2023.
The Company's dividends are designated as eligible dividends for Canadian tax purposes in accordance with subsection 89(14) of the Income Tax Act (Canada), and any applicable corresponding provincial and territorial legislation.
About Sienna Senior Living
Sienna Senior Living Inc. (TSX:SIA) offers a full range of seniors' living options, including independent living and assisted living under its Aspira retirement brand, long-term care, and specialized programs and services. Sienna's approximately 12,000 employees are passionate about cultivating happiness in daily life. For more information, please visit www.siennaliving.ca.
For further information, please contact: David Hung Chief Financial Officer & Executive Vice President (905) 489-0258 [email protected]
CV Sciences, Inc. (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced that it has consummated...
Kodiak Sciences Inc. , a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that the first patients with diabetic retinopathy...
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today announced that the Center for Drug...
Cannabix Technologies Inc. (the "Company or Cannabix") reports that it has entered into an arm's length marketing agreements with the following parties: Effective May 13, 2024, the Company has engaged Financial Buzz Media Networks LLC ("FBMN") for...
It is with great pleasure that we announce the Federal Commission for Protection against Health Risks (COFEPRIS) in Mexico has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks...
Kelyniam Global , a maker of custom cranial implants, today announced results for its quarter ended March 31, 2024.
Financial highlights for the three months ended March 31, 2024 and the same period in 2023 include:
Total revenue of $957,447...
